Merit Medical Systems (MMSI) was Downgraded by Barrington Research to ” Mkt Perform”. Earlier the firm had a rating of “Outperform ” on the company shares. Barrington Research advised their investors in a research report released on Jul 28, 2016.
On the company’s financial health, Merit Medical Systems reported $0.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.24. The company had revenue of $151.07 million for the quarter, compared to analysts expectations of $147.76 million. The company’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.25 EPS.
Merit Medical Systems opened for trading at $23.63 and hit $23.9 on the upside on Thursday, eventually ending the session at $23.47, with a gain of 1.16% or 0.27 points. The heightened volatility saw the trading volume jump to 8,34,365 shares. Company has a market cap of $1,040 M.
In a different news, on Mar 8, 2016, Kent W Stanger (director) sold 5,000 shares at $19.34 per share price. According to the SEC, on Dec 17, 2015, Fred P Lampropoulos (President & CEO) sold 3,125 shares at $18.47 per share price. On Dec 11, 2015, A Scott Anderson (director) sold 10,600 shares at $18.45 per share price, according to the Form-4 filing with the securities and exchange commission.
Merit Medical Systems Inc. (Merit) is a designer developer manufacturer and marketer of medical devices used in an array of interventional and diagnostic procedures across the world. The Company operates in the diagnostic and interventional cardiology interventional radiology interventional gastroenterology interventional pulmonology thoracic surgery interventional nephrology vascular surgery oncology electrophysiology cardiac rhythm management and pain management markets. It operates in segments: cardiovascular and endoscopy. Its cardiovascular segment comprises cardiology and radiology devices which assist in diagnosing and treating coronary arterial disease peripheral vascular disease and other non-vascular diseases and includes the embolotherapeutic products. Its endoscopy segment comprises gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal tracheobronchial and biliary strictures caused by malignant tumors.